Purging of epithelial tumor cells from peripheral blood stem cells by means of the bispecific antibody BIS-1

Clinical Cancer Research

Volumn 6, Issue 6, 2000, Pages 2521-2527

  Schröder, Carolien P ^a   Kroesen, Bart Jan ^a   De Leij, Lou F M H ^a   De Vries, Elisabeth G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; INTERLEUKIN 2; OKT 3; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL KILLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLYSIS; HUMAN; HUMAN CELL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION;

ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CHROMIUM RADIOISOTOPES; FEMALE; FLOW CYTOMETRY; GLYCOPROTEINS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTERLEUKIN-2; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; STEM CELLS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0343238219     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Brenner, M. K., Rill, D. R., Moen, R. C., Krance, R. A., Mirro, J., Anderson, W. F., and Ihle, J. N. Gene-marking to trace the origin of relapse after autologous bone-marrow transplantation. Lancet, 341: 85-86, 1993.
2. Deisseroth, A. B., Zu, Z., and Claxto, D. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood. 83: 3068-3076, 1994.
3. Kvalheim, G., Wang, M. Y., Pharo, A., Holte, H., Jacobsen, E., Beiske, K., Kvaloy, S., Smeland, E., Funderud, S., and Fodstad, T. Purging of tumor cells from leukapheresis products: experimental and clinical aspects. J. Hematother., 5: 427-436, 1996.
4. Champlin, R. Purging: elimination of malignant cells from autologous blood or marrow transplants. Curr. Opin. Oncol., 8: 79-83, 1996.
5. Passos-Coehho, J., Ross, A., Davis, J. M., Huelskamp, A., Clarke, B., Noga, S. J., Davidson, N. E., and Kennedy, M. J. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide. Cancer Res., 54: 2366-2371, 1994.
6. Mapara, M. Y., Körner, I. J., Hildebrandt, M., Bargou, R., Krahl, D., Reichardt, P., and Dörken, B. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical staining and reverse transcriptase-polymerase chain reaction. Blood, 89: 337-344, 1997.
7. Mehta, Y., Powles, R., Treleaven, J., Horton, C., Sheperd, V., Hale, G., Waldmann, H., and Singhal, S. Autologous transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia: long term follow up. Leuk. Lymphoma, 25: 479-486, 1997.
8. Seiden, M., Schlossman, R., Andersen, J., Freeman, A., Robertson, M., Soiffer, R., Freedman, A., Mauch, P., Ritz, J., Nadler, L., and Anderson, K. Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Leuk. Lymphoma, 17: 87-93, 1995.
9. Dyer, M., Kelsey, S., Mackay, H., Emmett, E., Thornton, P., Hale, G., Waldmann, H., Newland, A., and Catovsky, D. In vivo purging of residual disease in CLL with Campath-1H. Br. J. Haematol., 97: 669-672, 1997.
10. Freedman, A., Neuberg, D., Gribben, J., Mauch, P., Soiffer, R., Fisher, D., Anderson, K., Andersen, N., Schlossman, R., Kroon, M., Ritz, J., Aster, J., and Nadler, L. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long term remission. J. Clin. Oncol.16: 13-18, 1998.
11. Dreger, P., van Neuhoff, N., Suttorp, M., Löffler, and Schmitz, N. Rapid engraftment of peripheral blood progenitor cell grafts purged with B-cell specific monoclonal antibodies and immunomagnetic beads. Bone Marrow Transplant., 16: 627-629, 1995.
12. Gribben, J., Freedman, A., Nueberg, D., Roy, D., Blake, K., Woo, S., Grossbard, M., Rabinowe, S., Coral, F., Freman, G., Ritz, J., and Nadler, L. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N. Engl. J. Med., 325: 1525-1533, 1991.
13. Riethmüller, G., Schneider-Gädicke, E., Schlimok, G., Schmiegel, W., Raab, R., Höffken, K., Gruber, R., Pilchmaier, R., Buggisch, P., and Witte, J. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet, 343: 1177-1183, 1994.
14. Kroesen, B. J., Buter, J., Sleijfer, D. T., Jansen, R. A. J., van der Graaf, W. T. A., The, T. H., de Leij, L., and Mulder, N. H. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br. J. Cancer, 70: 652-661, 1994.
15. Valone, F. H., Kaufman, P. A., Gyure, P. M., Lewis, L. D., Memoli, V., Deo, Y., Graziano, R., Fisher, J. L., Meyer, L., and Mrozek Orlowski, M. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpress the protooncogene HER-2/neu. J. Clin. Oncol., 13: 2281-2292, 1995.
16. Weiner, L. M., Clark, J. I., Ring, D. B., and Alpaugh, R. K. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc γRIII. J. Hematotherapy, 4: 453-456, 1995.
17. Riethmüller, G., Holz, E., Schlimok, G., Schmiegel, W., Raab, R., Hofken, K., Gruber, R., Funke, I., Pilchmaier, H., Hirche, H., Bugisch, P., Witte, J., and Pilchmayr, T. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J. Clin. Oncol., 16: 1788-1794, 1998.
18. Cobleigh, M., Vogel, C., Tripathy, D., Robert, N., Scholl, S., Fehrenbacher, L., Paton, V., Shak, S., Lieberma, G., and Slamon, D. Efficacy and safety of Herceptin J (humanized anti-her2 antibody) as a single agent in 222 women with Her2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc. Am. Assoc. Clin. Oncol., 376: 97a, 1998.
19. Mykleburst, A. T., Godal, A., Juell, S., Pharo, A., and Fodstad, T. Comparison of two antibody based methods for elimination of breast cancer cells from human bone marrow. Cancer Res., 54: 209-214, 1994.
20. Spyridonidis, A., Schmidt, M., Bernardt, W., Papadimitriou, A., Azemar, M., Wels, W., Groner, B., and Henschler, R. Purging of mammary carcinoma cells during ex vivo culture of CD34+ hematopoietic progenitor cells with recombinant immunotoxins. Blood, 91: 1820-1827, 1998.
21. Verma, U. N., Areman, E., Dickerson, S. A., Kotula, P. L., Sacher, R., and Mazumder, A. Interleukin-2 activation of chemotherapy and growth factor-mobilized peripheral blood stem cells for generation of cytotoxic effectors. Bone Marrow Transplant., 15: 199-206, 1995.
22. Areman, E., Mazumder, A., Kotula, P., Verma, U., Rajagopal, C., Hancock, S., Guevarra, C., Djahanmir, M., Sacher, R., and Meehan, K. Hematopoietic potential of IL-2 cultured peripheral blood stem cells from breast cancer patients. Bone Marrow Transplant., 18: 521-525, 1996.
23. Scheffold, C., Brandt, K., Johnston, V., Lefterova, P., Degen, B., Schöntube, M., Huhn, D., Neubacher, A., and Schmidt-Wolf, I. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplant., 15: 33-39, 1995.
24. Kaneko, T., Fusauch, Y., Kakui, Y., Okumura, K., Mizouchi, H., and Oshimi, K. Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells. Leuk. Lymphoma, 14: 219-229, 1994.
25. Kroesen, B. J., Helfrich, W., Molema, G., and de Leij, L. Bispecific antibodies for treatment of cancer in experimental animal models and man. Adv. Drug. Delivery Rev., 31: 105-129, 1998.
26. de Leij, L., Helfrich, W., Stein, R., and Mattes, M. J. SLCL-cluster 2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2. Int. J. Cancer. 57: 60-63, 1994.
27. Kroesen, B. J., ter Haar, A., Spakman, H., Willemse, P. H. B., Sleijfer, D. T., de Vries, E. G. E., Mulder, N. H., Berendsen, H. H., Limburg, P. C., The, T. H., and de Leij, L. Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunol. Immunother., 37: 400-407, 1993.
28. de Vries, E. G. E., ten Vergert, E. M., Mastenbroek, C. G., Dalesio, O., and Rodenhuis, S. Breast cancer studies in the Netherlands. Lancet, 348: 407-408, 1996.
29. de Leij, L., Postmus, P. E., Buys, C. H. C. M., Elema, J. D., Ramaekers, F., Poppema, S., Brouwer, M., van der Veen, A. Y., Mesander, G., and The, T. H. Characterization of three new variant cell lines derived from small cell carcinoma of the lung. Cancer Res., 45: 6024-6033, 1985.
30. r double mutants. J. Immunol., 117: 1-8, 1989.
31. Vellenga, E., de Wolf, J. T., Beentjes, J. A., Esselink, M. T., Smit, J. W., and Halie, M. R. Divergent effects of interleukin-4 (IL-4) on the granulocyte colony-stimulating factor and IL-3-suppported myeloid colony formation from normal and leukemic bone marrow cells. Blood, 75: 633-637, 1990.
32. Ross, A. A., Cooper, B. W., Lazarus, H. M., Mackay, W., Moss, T. J., Ciobanu, N., Tallmann, M. S., Kennedy, M. J., Davidson, N. E., Sweet, D., Winter, C., Akard, L., Jansen, J., Copelan, E., Meagher, R. C., Herzig, R. H., Klumpp, T. R., Kahn, D. G., and Warner, N. E. Detection and viability of tumor cells in peripheral blood collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood, 82: 2605-2610, 1993.
33. Brügger, W., Brass, K. J., Glatt, M., Weber, F., Mertelsmann, R., and Kanz, L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood, 83: 636-640, 1994.
34. Helfrich, W., Ten Poele, R., Meersma, G. J., Mulder, N. H., de Vries, E. G. E., de Leij, L. F. M. H., and Smit, E. F. A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral blood. Br. J. Cancer, 76: 29-35, 1997.
35. Lowenthal, R. M., Faberes, C., Marit, G., Boiron, J. M., Cony-Makhoul, P., Pigneux, A., Agape, P., Vezon, G., Bouzgarou, R., Dazey, B., Fizet, D., Bernard, P., Lacombe, F., and Reiffers, J. Factors influencing haematopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: a retrospective analysis of a 10-year single institution experience. Bone Marrow Transplant., 22: 763-770, 1998.
36. Attisano, C., Bianchi, A., Montacchini, L., Carolesso, N., Peola, S., Bruno, B., Roux, V., Ferrero, D., Gallo, E., Boccadero, M., Pileri, A., and Massaia, M. Generation of anti-tumour activity by OKT3-stimulation in multiple myeloma: in vitro inhibition of autologous haemopoiesis. Br. J. Haematol., 87: 494-502, 1994.
37. Bhatia, R., Verfaillie, C., and McGlave, P. T lymphocytes grown from chronic leukemia bone marrow suppress autologous leukemia progenitors. Clin. Res., 39: 748A, 1991.
38. Buter, J., Janssen, R. A. J., Martens, A., Sleijfer, D. T., de Leij, L., and Mulder, N. H. Phase I/II study of low dose intravenous OKT3 and subcutaneous IL-2 in metastatic cancer. Eur. J. Cancer, 29A: 2108-2113, 1993.
39. Margolin, K. A., Wright, C., and Forman, S. J. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells. Leukemia, 9: 723-728, 1997.
40. Chabanon, C., Cornetta, K., Lotz, J-P., Rosenfeld, C., Shlomchik, M., Yanovitch, S., Marolleau, J-P., Sledge, G., Novakovitch, G., Srour, E. F., Burtness, B., Camerlo, J., Gravs, G., Lee-Fischer, J., Faucher, C., Chabbert, I., Krause, D., Maraninchi, D., Mills, B., Oldham, F., Blaise, D., and Viens, P. High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood stem cells in patients with poor-prognosis breast cancer: a randomized multicentre study. Br. J. Cancer, 78: 913-921, 1998.
41. Mapara, M. Y., Korner, I. J., Lentzsch, S., Krahl, D., Reichardt, P., and Dorken, B. Combined positive/negative purging and transplantation of peripheral blood progenitor cell autografts in breast cancer patients: a pilot study. Exp. Hematol., 27: 169-175, 1999.